AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 192 min read$DFTX

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.

Original reporting
finance.yahoo.com
Published Sep 19, 2026, 11:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 20, 2026, 3:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$DFTXBullishHigh
01

Why it matters

The Phase III data provides the first robust efficacy signal for DT120, setting the stage for an NDA submission in early 2027.

02

Market read

Positive trial data is likely to trigger a price rally and increase analyst coverage for DFTX.

03

What to watch

Potential competition from other GAD candidates and the need for payer acceptance could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Definium Therapeutics, formerly MindMed, is a clinical‑stage biotech focusing on brain‑health disorders.

Company-level read

Ticker impact

$DFTXBullishHigh confidence
Context

Definium Therapeutics reported positive Phase III results for DT120 in generalized anxiety disorder, showing statistically significant improvements over placebo.

Expected impact

Potential short‑term rally as investors price in the successful trial and upcoming NDA filing.

Evidence & confidence

Phase III success is material for a clinical‑stage biotech and precedes an FDA filing, historically moving share price sharply.

Market effects

Sector

Strengthens the GAD/psychiatric drug pipeline outlook, may boost peer biotech valuations.

Regional

Positive for US biotech sector, limited regional effect.

Global

Highlights continued innovation in mental‑health therapeutics globally.

Counterpoint

What could challenge this read

If regulatory scrutiny tightens on novel anxiolytics, the stock could face headwinds despite trial success.

Key entities

  • Executive
    Rob Barrow

    CEO of Definium Therapeutics, outlined regulatory filing timeline.

  • Product
    DT120

    Lead candidate for generalized anxiety disorder, showed 32% response vs 14% placebo.

Read at source← All news

Related articles

SEP 20
$DFTXMedAI 8/10

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.

yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.

simplywall.st3 min
SEP 17
$DFTXMed

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

stocktwits.com2 min